Several reports have demonstrated that buparlisib inhibits cell proliferation, diminishes metabolic activity, and exerts cytotoxic effects on solid tumors and hematological malignancies, including AML, by selective inhibition of Akt activity [187,188,189,190]. Here, AKT1 is linked to acute myeloid leukemia.